Insulin resistance impairs nigrostriatal dopamine function
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Clinical studies have indicated a link between Parkinson's disease (PD) and Type 2 Diabetes. Although preclinical studies have examined the effect of high-fat feeding on dopamine function in brain reward pathways, the effect of diet on neurotransmission in the nigrostriatal pathway, which is affected in PD and parkinsonism, is less clear. We hypothesized that a high-fat diet, which models early-stage Type 2 Diabetes, would disrupt nigrostriatal dopamine function in young adult Fischer 344 rats. Rats were fed a high fat diet (60% calories from fat) or a normal chow diet for 12 weeks. High fat-fed animals were insulin resistant compared to chow-fed controls. Potassium-evoked dopamine release and dopamine clearance were measured in the striatum using in vivo electrochemistry. Dopamine release was attenuated and dopamine clearance was diminished in the high-fat diet group compared to chow-fed rats. Magnetic resonance imaging indicated increased iron deposition in the substantia nigra of the high fat group. This finding was supported by alterations in the expression of several proteins involved in iron metabolism in the substantia nigra in this group compared to chow-fed animals. The diet-induced systemic and basal ganglia-specific changes may play a role in the observed impairment of nigrostriatal dopamine function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“The homeostatic model assessment of insulin resistance (HOMA-IR) is often used to obtain a global measure of insulin resistance (Wallace et al., 2004).”
MethodRegulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756 · cited 2×
“We also measured SN levels of hepcidin, which can control ferroportin through posttranslational modification (Nemeth and Ganz, 2006).”
MethodCross-Talk Between Iron Metabolism and Diabetes
Fernández-Real, J. M., López-Bermejo, A., & Ricart, W. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2348 · Cited by 704
The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia: Two Roads Converged
Craft, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.27 · Cited by 547 · cited 2×
“In the context of Alzheimer's disease, insulin has been shown to increase levels of the amyloid beta 42 (Craft, 2009), possibly by interacting with insulin degrading enzyme, which degrades amyloid beta (Qiu et al., 1997).”
BackgroundRichardson, D. R., Lane, D. J. R., Becker, E. M., Huang, M. L.-H., Whitnall, M., Rahmanto, Y. S., Sheftel, A. D., & Ponka, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912925107 · Cited by 536
Brain IRS2 Signaling Coordinates Life Span and Nutrient Homeostasis
Taguchi, A., Wartschow, L. M., & White, M. F. (2007) · Science · doi:10.1126/science.1142179 · Cited by 523 · cited 2×
“Insulin receptor substrate 2 (IRS2), a main modulator of brain insulin signaling, can negatively regulate memory formation (Irvine et al., 2011), and calorie restriction (through decreased IRS2 mediated insulin signaling) has been linked to increased longevity (Taguchi et al., 2007).”
BackgroundBaura, G. D., Foster, D. M., Porte, D., Kahn, S. E., Bergman, R. N., Cobelli, C., & Schwartz, M. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116773 · Cited by 489
The source of cerebral insulin
Banks, W. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.040 · Cited by 489 · cited 2×
“Because insulin can cross the blood brain barrier (Banks, 2004) and insulin receptors exist in the SN (Moroo et al., 1994), it is possible that iron transport was altered by the increased insulin levels produced by our HF diet.”
BackgroundType 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Insulin signaling in the central nervous system: Learning to survive
van der Heide, L. P., Ramakers, G. M. J., & Smidt, M. P. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.06.003 · Cited by 444 · cited 1×
“Intranasal insulin has been consistently shown to improve memory, and insulin signaling can positively affect cell survival (van der Heide et al., 2006; Benedict et al., 2011).”
Background
Cited by
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Hölscher, C. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0221 · Cited by 288
Metadata
- Authors
- Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P.-P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 231
- Issue
- 1
- Pages
- 171-180
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2004416309
- Cited by
- 150
- References
- 19
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin resistance impairs nigrostriatal dopamine function. https://app.cochat.ai/papers/10.1016/j.expneurol.2011.06.005
- The paper
- Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P.-P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A. (2011). Insulin resistance impairs nigrostriatal dopamine function. Experimental Neurology. https://doi.org/10.1016/j.expneurol.2011.06.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.